MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas
- PMID: 21311951
- DOI: 10.1007/s11060-011-0532-6
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas
Abstract
MGMT promoter hypermethylation of aggressive pituitary adenomas and pituitary carcinomas and low protein expression are implicated in improved response to treatment with temozolomide (TMZ). The aim of the present study was to investigate MGMT promoter methylation and immunoexpression in an aggressive subset of pituitary adenomas and carcinomas. Our material consisted of 12 silent subtype 3 (SS3) adenomas, 10 primary carcinomas, and 4 disseminated metastases. Two different tissue samples of 7 of the 12 SS3 adenomas and all carcinomas were analyzed for MGMT promoter methylation and immunohistochemical expression of MGMT. Immunoexpression was assessed semi-quantitatively as a percentage of immunoreactive nuclei. Overall 33% of carcinomas exhibited homogenous MGMT methylation in tumor and metastatic specimens. Low immunohistochemical MGMT expression was noted in 50% of carcinomas. Overall, 42% of the SS3 adenomas exhibited MGMT promoter methylation. MGMT immunostaining was predominantly negative (92%), with homogenous immunostaining results across different samples. Whereas all the methylated SS3 adenomas had low MGMT immunoreactivity, five unmethylated adenomas exhibited absent/low MGMT expression. There was no relationship between methylation status and MGMT immunoexpression was not apparent. MGMT methylation and low immunohistochemical expression seen in a subset of carcinomas and SS3 adenomas, suggesting that a subset of tumors may respond to treatment with TMZ. Heterogeneous MGMT methylation status in SS3 adenomas and the lack of concordance between methylation and immunohistochemical expression of MGMT suggest complex regulatory mechanisms, highlighting the need for improved methods in the research on a correlation between MGMT changes and response to TMZ.
Similar articles
-
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Med Mol Morphol. 2014 Mar;47(1):1-7. doi: 10.1007/s00795-013-0050-z. Epub 2013 Aug 17. Med Mol Morphol. 2014. PMID: 23955641 Review.
-
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.Endocrine. 2011 Oct;40(2):222-7. doi: 10.1007/s12020-011-9485-y. Epub 2011 May 15. Endocrine. 2011. PMID: 21792693
-
Treatment of pituitary neoplasms with temozolomide: a review.Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Epub 2010 Sep 15. Cancer. 2011. PMID: 20845485 Review.
-
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21. J Clin Endocrinol Metab. 2010. PMID: 20660056
-
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.Endocr Pathol. 2010 Sep;21(3):161-5. doi: 10.1007/s12022-010-9120-0. Endocr Pathol. 2010. PMID: 20480258
Cited by
-
Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.Endocrinol Metab (Seoul). 2023 Dec;38(6):631-654. doi: 10.3803/EnM.2023.1838. Epub 2023 Nov 15. Endocrinol Metab (Seoul). 2023. PMID: 37964483 Free PMC article. Review.
-
Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1585-1601. doi: 10.1210/clinem/dgad098. J Clin Endocrinol Metab. 2023. PMID: 36856733 Free PMC article.
-
High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens). 2022 Mar;21(1):1-14. doi: 10.1007/s42000-021-00333-y. Epub 2022 Jan 21. Hormones (Athens). 2022. PMID: 35061210 Review.
-
Genetic and Epigenetic Causes of Pituitary Adenomas.Front Endocrinol (Lausanne). 2021 Jan 26;11:596554. doi: 10.3389/fendo.2020.596554. eCollection 2020. Front Endocrinol (Lausanne). 2021. PMID: 33574795 Free PMC article. Review.
-
Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.Endocr Rev. 2020 Dec 1;41(6):821-46. doi: 10.1210/endrev/bnaa006. Endocr Rev. 2020. PMID: 32201880 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials